Vitamin D as a Potential Therapy for Multiple Sclerosis: Where Are We?

Area of Science:

• Neuroimmunology
• Endocrinology
• Demyelinating diseases

Background:

• Multiple sclerosis (MS) is a chronic central nervous system demyelinating disease driven by an aberrant immune response.
• Current disease-modifying therapies improve treatment but do not halt disease progression.
• Emerging evidence highlights the immunomodulatory and neuroprotective roles of active vitamin D (1,25(OH)2D).

Purpose of the Study:

• To review the therapeutic potential of vitamin D in multiple sclerosis (MS) and its animal models.
• To discuss the challenges associated with vitamin D supplementation for MS treatment.
• To explore alternative strategies for effective vitamin D-based MS therapy.

Main Methods:

• Review of current literature on vitamin D supplementation in experimental autoimmune encephalomyelitis (EAE) and MS clinical trials.
• Analysis of the immunomodulatory mechanisms of 1,25(OH)2D relevant to MS.
• Discussion of alternative strategies to circumvent vitamin D therapy limitations.

Main Results:

• 1,25(OH)2D demonstrates potential by suppressing pathogenic T cells, enhancing regulatory T cells, and promoting remyelination.
• Clinical trials using native vitamin D supplementation for MS have yielded mixed results.
• Hypercalcemia associated with high 1,25(OH)2D concentrations presents a significant hurdle for therapeutic use.

Conclusions:

• Vitamin D possesses promising properties for MS treatment, including immune modulation and remyelination support.
• Overcoming the hypercalcemia side effect is critical for developing effective vitamin D-based MS therapies.
• Further research into alternative vitamin D forms and strategies is essential to realize its therapeutic potential in MS.